Metronomic capecitabine
Showing 1 - 25 of 1,464
to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally
Recruiting
- to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma
- Capecitabine 500Mg Oral Tablet
-
Shanghai, ChinaEye & ENT Hospital, Fudan University
Jul 2, 2023
Nasopharyngeal Carcinoma Trial in Singapore (CCRT with Maintenance Tislelizumab and Metronomic Capecitabine)
Not yet recruiting
- Nasopharyngeal Carcinoma
- CCRT with Maintenance Tislelizumab and Metronomic Capecitabine
-
Singapore, Singapore
- +1 more
Oct 16, 2023
Metastatic Pancreatic Cancer Trial in Singapore (Low Dose OXIRI (LD-OXIRI))
Not yet recruiting
- Metastatic Pancreatic Cancer
- Low Dose OXIRI (LD-OXIRI)
-
Singapore, SingaporeNational Cancer Centre, Singapore
Jun 29, 2023
Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)
Active, not recruiting
- Breast Cancer
- Capecitabine
- Aromatase Inhibitor
-
Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen Uni
Jan 27, 2023
Triple Negative Breast Cancer Trial in Guangzhou (Capecitabine, Tucidinostat)
Recruiting
- Triple Negative Breast Cancer
-
Guangzhou, Guangdong, ChinaSun-yat sen university cancer center
Nov 1, 2022
Breast Cancer Trial in Zhengzhou (Capecitabine+endocrine therapy, Placebo+endocrine therapy)
Recruiting
- Breast Cancer
- Capecitabine+endocrine therapy
- Placebo+endocrine therapy
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Nov 19, 2022
Breast Tumors, Locally Advanced or Metastatic Breast Cancer Trial in Guangzhou (Taxane plus Intermittent Capecitabine, Utidelone
Not yet recruiting
- Breast Neoplasms
- Locally Advanced or Metastatic Breast Cancer
- Taxane plus Intermittent Capecitabine
- +3 more
-
Guangzhou, Guangdong, ChinaShusen Wang
Dec 27, 2021
Nasopharyngeal Carcinoma Trial in Guangzhou (PD-1 antibody, Capecitabine)
Recruiting
- Nasopharyngeal Carcinoma
- PD-1 antibody
- Capecitabine
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Apr 17, 2022
Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) Trial in Shanghai (Capecitabine,
Recruiting
- Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)
- Capecitabine, Camrelizumab
-
Shanghai, ChinaDepartment of Oncology, Ruijin Hospital
Sep 16, 2021
Colo-rectal Cancer, Metastatic Cancer Trial in Besançon, Dijon, Montbéliard (Regorafenib, Cyclophosphamide, Capecitabine)
Active, not recruiting
- Colo-rectal Cancer
- Metastatic Cancer
- Regorafenib
- +3 more
-
Besançon, France
- +2 more
Jan 24, 2023
Breast Cancer Trial in Beijing (oral vinorelbine and capecitabine)
Recruiting
- Breast Cancer
- oral vinorelbine and capecitabine
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Feb 27, 2023
Head and Neck Squamous Cell Carcinoma Trial in Guangzhou (Capecitabine)
Recruiting
- Head and Neck Squamous Cell Carcinoma
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Feb 15, 2022
Metastatic Colorectal Cancer Trial in France (other, procedure, drug)
Not yet recruiting
- Metastatic Colorectal Cancer
- quality of life questionnaires
- +6 more
-
Besançon, France
- +6 more
Jul 15, 2022
Advanced Cervical Cancer Trial in Shanghai (Capecitabine, camrelizumab)
Recruiting
- Advanced Cervical Cancer
- Capecitabine, camrelizumab
-
Shanghai, ChinaDepartment of Oncology, Ruijin Hospital
Jan 27, 2021
Neuroendocrine Tumors, Gastro Entero Pancreatic Neuroendocrine Tumors Trial in Meldola, Milan (28 GBq 177Lu-DOTATATE, 22 GBq
Active, not recruiting
- Neuroendocrine Tumors
- Gastro Entero Pancreatic Neuroendocrine Tumors
- 28 GBq 177Lu-DOTATATE
- 22 GBq 177Lu-DOTATATE
-
Meldola, FC, Italy
- +1 more
Feb 25, 2021
HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer Trial in Los Angeles (drug, biological, other)
Terminated
- HER2-positive Breast Cancer
- +2 more
- capecitabine
- +4 more
-
Los Angeles, CaliforniaUSC Norris Comprehensive Cancer Center
Aug 22, 2021
Metastatic Breast Cancer Trial in Beijing (Vinorelbine 40mg, Toripalimab 240mg, Bevacizumab 5 mg/kg)
Recruiting
- Metastatic Breast Cancer
- Vinorelbine 40mg
- +5 more
-
Beijing, Beijing, China
- +1 more
Feb 9, 2022
Pancreatic Cancer Trial in Shanghai (Capecitabine)
Recruiting
- Pancreatic Cancer
-
Shanghai, ChinaDepartment of Oncology, Ruijin Hospital
Apr 29, 2021
Breast Cancer, Estrogen Receptor-positive Breast Cancer, Metastatic Breast Cancer Trial in Cairo (Capecitabine, Letrozole 2.5mg)
Unknown status
- Breast Cancer
- +2 more
- Capecitabine
- Letrozole 2.5mg
-
Cairo, EgyptFaculty of Medicine, Cairo University
Sep 25, 2020
Head Neck Cancer, Esophageal Squamous Cancer Trial in Shanghai (Capecitabine, Camrelizumab)
Recruiting
- Head and Neck Cancer
- Esophageal Squamous Cancer
- Capecitabine, Camrelizumab
-
Shanghai, ChinaDepartment of Oncology, Ruijin Hospital
Aug 12, 2020
Colorectal Cancer Trial in Shanghai (Capecitabine)
Terminated
- Colorectal Cancer
-
Shanghai, ChinaDepartment of Oncology, Ruijin Hospital
Apr 28, 2021